<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128214</url>
  </required_header>
  <id_info>
    <org_study_id>8299</org_study_id>
    <nct_id>NCT05128214</nct_id>
  </id_info>
  <brief_title>Aspirin Thromboprophylaxis After First-line Total Hip and Knee Replacement</brief_title>
  <acronym>TBP-ASPIR</acronym>
  <official_title>Aspirin Thromboprophylaxis After First-line Total Hip and Knee Replacement. Comparison With Baseline Low Molecular Weight Heparin Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Annually, more than 100,000 total hip prostheses (THA) and more than 100,000 total knee&#xD;
      prostheses (TKA) are implanted for osteoarthritis in France, and these figures are set to&#xD;
      increase significantly in the future as in all industrialized countries. . Venous thrombosis&#xD;
      is a potentially serious complication after PTH and PTG, justifying various prophylactic&#xD;
      measures. In France, aggressive prophylaxis with low molecular weight heparin (LMWH) or&#xD;
      direct oral anticoagulants (DOA) was until recently recommended, because this drug is&#xD;
      considered to be the most effective, at the cost of a bleeding risk implicitly assumed but&#xD;
      often poorly. evaluated. A recent publication suggests that the risk of bleeding is currently&#xD;
      greater than the risk of a thromboembolic event.&#xD;
&#xD;
      More recently, foreign or international recommendations have broadened the range of these&#xD;
      recommendations, notably by introducing aspirin as a possible prophylactic agent. While this&#xD;
      molecule is potentially less effective than LMWHs or ADOs, it could decrease the risk of&#xD;
      iatrogenic hemorrhage. The introduction of enhanced recovery procedures after surgery (RAAC)&#xD;
      could decrease the risk of thrombosis without modifying the risk of bleeding, and thereby&#xD;
      improve the cost-benefit ratio of aspirin, justifying its recent inclusion in the current&#xD;
      French recommendations when The operated follows such a protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective study of the postoperative thromboembolic complications after implantation of hip and knee prostheses</measure>
    <time_frame>Files analysed retrospectively from July 01, 2016 to December 31, 2020 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hip and Knee Prosthesis Implantation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient operated on for a first-line total hip or knee replacement by the principal&#xD;
        investigator;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patient (≥ 18 years old);&#xD;
&#xD;
          -  Patient operated on for a first-line total hip or knee replacement by the principal&#xD;
             investigator;&#xD;
&#xD;
          -  Patient not having expressed his opposition, after information, to the reuse of his&#xD;
             data for the purposes of this research.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Subject having expressed opposition to participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Yves JENNY, MD, PhD</last_name>
    <phone>33 3 68 76 52 87</phone>
    <email>jean-yves.jenny@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Chirurgie Orthopédique Pédiatrique - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves JENNY, MD, PhD</last_name>
      <phone>33 3 68 76 52 87</phone>
      <email>jean-yves.jenny@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Yves JENNY, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre DIDIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip prosthesis implantation</keyword>
  <keyword>Knee prosthesis implantation</keyword>
  <keyword>Aspirin thromboprophylaxis</keyword>
  <keyword>Heparin prophylaxis</keyword>
  <keyword>Thromboembolic complications</keyword>
  <keyword>Bleeding complications</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

